THURSDAY, Oct. 15, 2020 — Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with
Continue reading »
Home »
High Circulating Prolactin Level Inversely Linked to T2DM Risk
FRIDAY, Oct. 12, 2018 — Among U.S. women, a normally high circulating prolactin concentration is associated with a reduced risk
Continue reading »
Lixisenatide Cuts Kidney Damage in T2DM and Coronary Syndrome
FRIDAY, Oct. 5, 2018 — For patients with type 2 diabetes and acute coronary syndrome, lixisenatide can slow or prevent
Continue reading »
HbA1c variability is a strong predictor of mortality in T2DM
(HealthDay)—Hemoglobin A1c (HbA1c) variability may be a more powerful predictor of all-cause mortality with type 2 diabetes than average HbA1c,
Continue reading »
Sulfonylureas as 2nd-line T2DM therapy tied to higher event risk
(HealthDay)—Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared
Continue reading »
Lactation lowers risk of T2DM after gestational diabetes
(HealthDay)—For women with previous gestational diabetes mellitus (GDM), lactation is associated with reduced risk of type 2 diabetes mellitus (T2DM),
Continue reading »
Lower energy consumption for South Asian migrants with T2DM
(HealthDay)—Among South Asian (SA) migrants in the United States, those with type 2 diabetes mellitus (T2DM) consume less total energy
Continue reading »